MedTrace Logo

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.

Conditions

  • Alzheimers Disease

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2022-05-20
Completion
2022-05-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05097131 on ClinicalTrials.gov